<DOC>
	<DOCNO>NCT01680406</DOCNO>
	<brief_summary>The investigator hypothesize addition primaquine ( PQ ) artemether-lumefantrine ( AL ) chloroquine ( CQ ) treatment Plasmodium vivax infection result decrease chance relapse 60 % . The investigator plan assess therapeutic efficacy AL compare combine AL + PQ CQ compare combine CQ + PQ P. vivax infection . They also plan determine number recurrent vivax episodes patient receive PQ compare n't receive PQ . Patients age 1 year symptomatic malaria present health center enrol treatment AL , AL+PQ , CQ , CQ+PQ P. vivax infection . Phase 1 study monitor clinical , parasitological , hematological parameter P. vivax infection 42-day follow-up period , used evaluate drug efficacy . Phase 2 continue monthly follow-up patient one year ass frequency recur vivax infection . Results research study use assist Ethiopia assess current national malaria drug policy .</brief_summary>
	<brief_title>Ethiopia Antimalarial Vivo Efficacy Study 2012</brief_title>
	<detailed_description>Following rapid development significant drug resistance Plasmodium falciparum ( Pf ) chloroquine sulfadoxine-pyrimethamine , artemether- lumefantrine ( Coartem AL ) adopt first line therapy Ethiopia 2004 . According current national malaria diagnosis treatment guideline updated 2012 , first-line treatment uncomplicated P. falciparum infection AL . First-line treatment Plasmodium vivax ( Pv ) chloroquine ( CQ ) alone malarious area primaquine non-malarious area health center hospital level . WHO recommend treatment Pv CQ artemisinin-based combination therapy ( ACT ) combination primaquine . For clinical infection without laboratory confirmation , AL first-line treatment since AL effective Pf Pv . Thus , Ethiopia , treatment malaria without laboratory confirmation occur frequently , Pv often treat AL standard care . Similarly , recommend drug mixed infection Pf Pv AL . Now wide-spread use AL CQ evidence malaria laboratory test occur half suspect clinical evidence malaria infection , investigator propose conduct antimalarial efficacy study monitor effectiveness therapy Ethiopia determine efficacious drug remain Pv . In addition , high rate relapse P. vivax infection , efficacy safety co-administering primaquine assess . This information inform future policy change respect appropriate antimalarial strategy .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Artemether-lumefantrine combination</mesh_term>
	<mesh_term>Artemisinins</mesh_term>
	<mesh_term>Lumefantrine</mesh_term>
	<mesh_term>Artemether</mesh_term>
	<mesh_term>Primaquine</mesh_term>
	<mesh_term>Chloroquine</mesh_term>
	<mesh_term>Chloroquine diphosphate</mesh_term>
	<mesh_term>Antimalarials</mesh_term>
	<criteria>Slideconfirmed infection P. vivax Age &gt; 1 year Lives within 20 km enrol health facility Weight ≥ 5.0 kg Axillary temperature ≥ 37.5º C history fever previous 48 hour Patient caregiver agree finger prick return visit . General danger sign symptom severe malaria ( see Annex II ) Signs symptom severe malnutrition , define weightforage ≤ 3 standard deviation mean ( NCHS/WHO normalize reference value ) Slide confirm infection Plasmodium specie . besides P. vivax monoinfection Acute anemia , define Hg &lt; 8 g/dl Known hypersensitivity drug evaluate Presence febrile condition cause disease malaria Serious chronic medical condition history ( cardiac , renal , hepatic disease , sickle cell disease , HIV/AIDS ) Pregnant breastfeed woman . History hemolysis severe anemia Regular medication , may interfere antimalarial pharmacokinetics</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Plasmodium vivax</keyword>
	<keyword>malaria</keyword>
	<keyword>Ethiopia</keyword>
	<keyword>Sub-Saharan Africa</keyword>
	<keyword>primaquine</keyword>
	<keyword>artemether lumefantrine</keyword>
	<keyword>chloroquine</keyword>
</DOC>